Edition:
United States

Arena Pharmaceuticals Inc (ARNA.O)

ARNA.O on Nasdaq

24.53USD
19 Sep 2017
Change (% chg)

-- (--)
Prev Close
$24.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
921,695
52-wk High
$27.86
52-wk Low
$11.30

Chart for

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $962.07
Shares Outstanding(Mil.): 39.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

BRIEF-Arena Pharmaceuticals Q2 loss per share $0.77

* Arena Pharmaceuticals provides corporate update and reports second quarter 2017 financial results

Aug 07 2017

BRIEF-Arena Pharmaceuticals says public offering of 6.25 mln common shares priced at $24 per share

* Arena Pharmaceuticals announces pricing of public offering of common stock

Jul 12 2017

BRIEF-Arena Pharmaceuticals announces proposed public offering of common stock

* Arena Pharmaceuticals announces proposed public offering of common stock

Jul 11 2017

Arena's heart-lung drug succeeds in mid-stage study, shares soar

U.S. drug developer Arena Pharmaceuticals Inc said on Monday its experimental drug for pulmonary arterial hypertension (PAH), a rare but deadly lung disease, met the main goal in a mid-stage study.

Jul 10 2017

BRIEF-Arena Pharmaceuticals Inc's board increased size of board from nine directors to ten directors

* Arena Pharmaceuticals Inc - on June 13, 2017, board of directors increased size of board from nine directors to ten directors Source text:(http://bit.ly/2rAYXbA) Further company coverage:

Jun 15 2017

BRIEF-Arena Pharmaceuticals says shareholders and board approve reverse stock split

* Arena Pharmaceuticals announces shareholders and board of directors approve reverse stock split

Jun 14 2017

BRIEF-Arena Pharmaceuticals reports Q1 loss per share $0.09

* Arena Pharmaceuticals provides corporate update and reports first quarter 2017 financial results

May 09 2017

BRIEF-Great Point Partners reports 9.75 pct passive stake in Arena Pharmaceuticals

* Great Point Partners LLC reports 9.75 percent passive stake in Arena Pharmaceuticals Inc as of April 18 - SEC filing Source: (http://bit.ly/2pdzPcX) Further company coverage:

Apr 28 2017

BRIEF-Arena Pharmaceuticals prices 60 mln shares of common stock at price of $1.15/share

* Arena Pharmaceuticals announces pricing of public offering of common stock

Apr 17 2017

BRIEF-Arena Pharmaceuticals announces proposed public offering of common stock

* Arena Pharmaceuticals announces proposed public offering of common stock Source text for Eikon: Further company coverage:

Apr 17 2017

Competitors

Earnings vs. Estimates